The initial focus of the new business area will be the launch of a range of animal free recombinant ingredients developed specifically for industrial scale mammalian cell culture. The range will deliver productivity, compliance and consistency whilst avoiding the regulatory, quality and performance issues often associated with animal and human-derived raw materials.
The design and manufacture of recombinant ingredients for the biopharmaceutical industry represents a natural and significant development in terms of Novozymes’ traditional business, expanding on the Company’s science led approach and its leadership and unsurpassed expertise in industrial scale microbial protein production. To support this development, Novozymes has gained a world-leading product and technology portfolio, as well as significant knowledge and expertise through the acquisition of Delta Biotechnology Ltd (now Novozymes Delta Ltd) and GroPep Ltd (now Novozymes GroPep Ltd) in July 2006 and December 2006, respectively. The Biopharmaceutical Ingredients business is headquartered in Nottingham UK.
“We are very excited by the launch of this new business and what it represents to the wider biopharmaceutical industry”, commented Peter Rosholm, recently appointed Vice President for the Ingredients business area. “We have combined Novozymes expertise in large scale protein production and supply with a strong science base to provide a range of products specifically developed for biopharmaceutical production. In addition to addressing the need to produce ever-safer biopharmaceuticals, our cell culture range has a secure supply network to deliver ingredients which allow for process optimisation whilst reducing customers regulatory and lot testing burdens. Our solution package exceeds what current animal derived and serum free supplements can provide industrial cell culture today”